Hejing Biotech announced that the holding subsidiary Shunjing Pharmaceutical reported phase Ib clinical study data of SGC001 injection in the form of a poster at the American Heart Association Scientific Annual Meeting. In terms of safety, the low, medium, and high dosage groups all showed good safety and tolerability. There were no adverse events in grade 3 or above treatment, no serious adverse events occurred, and there were no discontinuation of the drug due to adverse events. Cardiac magnetic resonance evaluation showed that the median percentage of myocardial infarction area decreased by 20.5% and 38.1%, respectively, in the medium to high dose group, and the three treatment groups were superior to the placebo group in improving microvascular obstruction.

Hejing Biotech announced that the holding subsidiary Shunjing Pharmaceutical reported phase Ib clinical study data of SGC001 injection in the form of a poster at the American Heart Association Scientific Annual Meeting. In terms of safety, the low, medium, and high dosage groups all showed good safety and tolerability. There were no adverse events in grade 3 or above treatment, no serious adverse events occurred, and there were no discontinuation of the drug due to adverse events. Cardiac magnetic resonance evaluation showed that the median percentage of myocardial infarction area decreased by 20.5% and 38.1%, respectively, in the medium to high dose group, and the three treatment groups were superior to the placebo group in improving microvascular obstruction.